title: Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat.
abstract: 5-lipoxygenase inhibitor and human recombinant erythropoietin might accelerate renal recovery in cisplatin-induced acute renal failure rats. Male Sprague-Dawley rats were randomized into four groups: 1) normal controls; 2) Cisplatin group-cisplatin induced acute renal failure (ARF) plus vehicle treatment; 3) Cisplatin+nordihydroguaiaretic acid (NDGA) group-cisplatin induced ARF plus 5-lipoxygenase inhibitor treatment; 4) Cisplatin+erythropoietin (EPO) group-cisplatin induced ARF plus erythropoietin treatment. On day 10 (after 7 daily injections of NDGA or EPO), urea nitrogen and serum Cr concentrations were significantly lower in the Cisplatin+NDGA and Cisplatin+EPO groups than in the Cisplatin group, and 24 hr urine Cr clearances were significantly higher in the Cisplatin+EPO group than in the Cisplatin group. Semi-quantitative assessments of histological lesions did not produce any significant differences between the three treatment groups. Numbers of PCNA(+) cells were significantly higher in Cisplatin, Cisplatin+NDGA, and Cisplatin+EPO groups than in normal controls. Those PCNA(+) cells were significantly increased in Cisplatin+NDGA group. These results suggest that EPO and also NDGA accelerate renal function recovery by stimulating tubular epithelial cell regeneration.
authors.affiliation: Department of Internal Medicine, Pusan National University School of Medicine, Seo-gu, Busan, Korea.
authors.forename: Dong Won
authors.initials: DW
authors.lastname: Lee
authors.forename: Ihm Soo
authors.initials: IS
authors.lastname: Kwak
authors.forename: Soo Bong
authors.initials: SB
authors.lastname: Lee
authors.forename: Sang Heon
authors.initials: SH
authors.lastname: Song
authors.forename: Eun Young
authors.initials: EY
authors.lastname: Seong
authors.forename: Byeong Yun
authors.initials: BY
authors.lastname: Yang
authors.forename: Min Young
authors.initials: MY
authors.lastname: Lee
authors.forename: Mee Young
authors.initials: MY
authors.lastname: Sol
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000188:drug therapy*; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000008:administration & dosage; D001806:Blood Urea Nitrogen; D002945:Cisplatin / Q000633:toxicity*; D003404:Creatinine / Q000652:urine; D004847:Epithelial Cells / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D007668:Kidney / Q000378:metabolism; D007684:Kidney Tubules / Q000187:drug effects; D008297:Male; D009637:Masoprocol / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012038:Regeneration
chemical_list: D004921:Erythropoietin; D009637:Masoprocol; D003404:Creatinine; D001094:Arachidonate 5-Lipoxygenase; D002945:Cisplatin